Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Extension Study in Hypereosinophilic Syndrome
NCT03306043Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoints: Number of Participants With Common (>=3%) Non-serious Adverse Events, Number of Participants With Serious Adverse Events and 1 more. Started Nov 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT03306043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306043.